Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F22%3A00013407" target="_blank" >RIV/00023736:_____/22:00013407 - isvavai.cz</a>
Alternative codes found
RIV/65269705:_____/22:00076115 RIV/00216208:11130/22:10444548 RIV/00064203:_____/22:10444548 RIV/00216224:14110/22:00126254
Result on the web
<a href="https://doi.org/10.1038/s41375-022-01612-2" target="_blank" >https://doi.org/10.1038/s41375-022-01612-2</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1038/s41375-022-01612-2" target="_blank" >10.1038/s41375-022-01612-2</a>

Result language
angličtina
Original language name
Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy
Original language description
Several studies have reported that chronic myeloid leukaemia (CML) patients expressing e14a2 BCR::ABL1 have a faster molecular response to therapy compared to patients expressing e13a2. To explore the reason for this difference we undertook a detailed technical comparison of the commonly used Europe Against Cancer (EAC) BCR::ABL1 reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) assay in European Treatment and Outcome Study (EUTOS) reference laboratories (n = 10).
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology

Project
<a href="/en/project/NU21-03-00128" target="_blank" >NU21-03-00128: BCR-ABL1-positive leukaemia - clinical and biological issues</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)